Seres Therapeutics closed at $2.09 on Nov 4, up 6.63%, 92.7% below its 52-week closing high. Volume of 95.0K shares was 1.27× its 20-day average (above normal).
Split-adjusted performance: -27.9% over one month, -73.9% over six months, -86.3% over one year.
In the quarter ended Jun 30, 2026, revenue was $736K, with a net margin of 622.4%.
Short interest was 312.3K shares at the Oct 15 settlement (4.4% of float, 3.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MCRBSeres Therapeutics | $2.09 | +6.63% | −73.9% | — | 622.4% | — | $21.0M | |
| TXMDTherapeuticsMD | $1.82 | +2.25% | −10.3% | −8.7% | 17.8% | — | $21.1M | Compare |
| EDSAEdesa Biotech | $2.17 | −4.82% | −85.5% | — | — | — | $20.9M | Compare |
| AYTUAYTU BioPharma | $1.92 | −0.52% | −25.0% | +6.4% | −0.1% | — | $20.9M | Compare |
| ATOSAtossa Therapeutics | $2.12 | −9.01% | −63.4% | — | — | — | $21.2M | Compare |
| IGCIGC Pharma | $0.1950 | +4.84% | −38.7% | −19.2% | −1107.9% | — | $20.2M | Compare |
| COCPCocrystal Pharma | $1.01 | −5.61% | −28.4% | — | −3013.3% | — | $19.5M | Compare |
| CNTXContext Therapeutics | $0.2035 | +4.90% | −91.6% | — | — | — | $18.7M | Compare |
| MIRAMIRA Pharmaceuticals | $0.5610 | +8.34% | −43.9% | — | — | — | $23.6M | Compare |
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
